Aldo Maggioni to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Aldo Maggioni has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.401
-
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019 05; 26(8):824-835.
Score: 0.082
-
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 04; 271:120-127.
Score: 0.077
-
[The REVEAL study]. G Ital Cardiol (Rome). 2018 Feb; 19(2):71-76.
Score: 0.077
-
Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. Int J Cardiol. 2017 Dec 01; 248:166-172.
Score: 0.074
-
Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. Int J Cardiol. 2017 Nov 01; 246:62-67.
Score: 0.072
-
Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc. 2017 Jul 05; 6(7).
Score: 0.018